Clinical trial
Detection of Serum Protein Biomarkers to Predict and Monitor Response to Infliximab Using SOMAscan
NCT04655729 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Detection of Serum Protein Biomarkers to Predict and Monitor Response to Infliximab Using SOMAscan
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- November 18, 2019
- Completion date
- January 1, 2023
- Enrollment
- 120 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.